PROGRAM CHAIR
Nikhil I. Khushalani, MD
Senior Member and Vice-Chair
Department of Cutaneous Oncology
H. Lee Moffitt Cancer Center
Tampa, Florida
PROGRAM OVERVIEW
Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin cancers. Most cases can be successfully managed with surgery and other local therapies, but patients with high-risk disease face an increased risk of recurrence, progression, and metastasis. Management of high-risk cSCC often requires multidisciplinary care, with radiation oncology playing an important role in definitive and postoperative treatment. As immunotherapy becomes increasingly integrated into the treatment landscape, radiation oncology clinicians must be prepared to identify patients at high risk for poor outcomes and determine how best to sequence and combine radiation therapy with systemic treatment. In this program, clinicians will learn to apply evidence-based clinical criteria to identify patients with high-risk cSCC and guide treatment decisions; evaluate clinical evidence supporting the sequencing and integration of neoadjuvant immunotherapy with radiation to inform individualized treatment planning; and implement evidence-based strategies for integrating adjuvant immunotherapy with postoperative radiation to improve disease control and prevent progression.
TARGET AUDIENCE
This activity is intended for radiation oncologists and their associated care teams involved in the multidisciplinary management of patients with cutaneous squamous cell carcinoma (cSCC).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Utilize evidence-based clinical criteria to identify patients with high-risk cSCC and guide treatment decisions that improve disease control and prevent progression.
- Apply clinical evidence supporting the sequencing and integration of neoadjuvant immunotherapy with radiation in high-risk cSCC to inform individualized treatment planning.
- Implement evidence-based strategies for integrating adjuvant immunotherapy with postoperative radiation in high-risk cSCC.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
AAPA CREDIT DESIGNATION STATEMENT – ENDURING
Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid until October 26, 2027.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Nikhil I. Khushalani, MD | Discloses that he has served as a Consultant/Advisory Board/Steering Committee member for: Bristol Myers Squibb, Delcath, Immunocore, Instil Bio, IO Biotech, Iovance Biotherapeutics, Merck, Mural Oncology, MyCareGorithm, Nektar Therapeutics, Novartis, Pfizer, Regeneron, Replimune, Sun Pharmaceuticals. He has received research funding (all to Institute): BMS, BioNTech, Celgene, GSK, HUYABIO International, IDEAYA, Merck, Modulation Therapeutics, Novartis, Regeneron, Replimune. He holds common stock in: Bellicum Pharmaceuticals. He serves on the Data and Safety Monitoring Committee for: AstraZeneca, Incyte Corporation. He receives travel support from: Castle Biosciences, Regeneron, HUYABIO International. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, Sr. VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, MA, CCRC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Nicholas Torres, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Lisa Kuhns, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 26, 2026
EXPIRATION DATE: October 26, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
